Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.76
Nov 19 • 3:59 PM ET Dollar change-0.06 Percentage change(-2.13%)
Aftermarket Close
2.76
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
111.79M
Enterprise Value
-50.73M
Income
-61.85M
Sales
0.00M
Book/sh
3.89
Cash/sh
4.03
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
45
IPO
Apr 09, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.71
P/C
0.68
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
18.84
Current Ratio
18.84
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-2.77
EPS next Y
-1.40
EPS next Q
-0.35
EPS this Y
63.41%
EPS next Y
13.04%
EPS next 5Y
30.38%
EPS past 3/5Y
40.79% 11.29%
Sales past 3/5Y
- -
EPS Y/Y TTM
55.14%
Sales Y/Y TTM
-
EPS Q/Q
67.10%
Sales Q/Q
-
Insider Own
31.26%
Insider Trans
-0.01%
Inst Own
73.13%
Inst Trans
9.52%
ROA
-51.56%
ROE
-55.18%
ROIC
-39.08%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
0.34%
SMA50
3.11%
SMA200
-23.63%
Trades
Shs Outstand
40.50M
Shs Float
27.84M
52W High
5.38 -48.70%
52W Low
2.01 37.31%
Volatility
12.68% 11.27%
ATR (14)
0.29
RSI (14)
50.24
Beta
0.16
Rel Volume
0.41
Avg Volume
330.68K
Volume
136,086
Perf Week
-8.31%
Perf Month
20.00%
Perf Quarter
-29.95%
Perf Half Y
-32.19%
Perf YTD
-4.83%
Perf Year
0.00%
Perf 3Y
-95.92%
Perf 5Y
-96.55%
Perf 10Y
-
Prev Close
2.82
Price
2.76
Change %
-2.13%
Consensus
Strong Buy
Avg. Price Target
$13.33
Implied Upside
+383.0%
Analysts11incl. previous ratings
Rating Distribution4 Buy · 6 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Apr 30, 2025Initiated
EVR logoEEvercore ISI
Outperform
Dec 05, 2024Initiated
LLeerink Partners
Outperform$33+1,095.7%
Oct 10, 2024Initiated
OPY logoOOppenheimer
Outperform$35+1,168.1%
Dec 15, 2023Downgrade
LLeerink Partners
Outperform → Market Perform
Dec 15, 2023Downgrade
JEF logoJJefferies
Buy → Hold
Dec 15, 2023Downgrade
HH.C. Wainwright
Buy → Neutral$30 → $1.50-45.7%
Dec 14, 2023Downgrade
WWilliam Blair
Outperform → Mkt Perform
Dec 14, 2023Downgrade
RRobert W. Baird
Outperform → Neutral$28 → $3+8.7%
Dec 14, 2023Downgrade
PPiper Sandler
Overweight → Neutral$25 → $4+44.9%
Dec 14, 2023Downgrade
LLadenburg Thalmann
Buy → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Saccomano Nicholas APresident and CEOSep 21 '26Sale2.978725911,160Sep 23 04:54 PM
Leverone Jason A.Chief Financial OfficerSep 21 '26Sale2.9730289818,500Sep 23 04:52 PM
Saccomano Nicholas APresident and CEOJun 22 '26Sale4.408637811,247Jun 24 07:29 PM
Leverone Jason A.Chief Financial OfficerJun 22 '26Sale4.403031,33218,802Jun 24 07:27 PM
Saccomano Nicholas APresident and CEOMar 23 '26Sale4.16863577,333Mar 24 06:57 PM
Leverone Jason A.Chief Financial OfficerMar 23 '26Sale4.163011,25116,000Mar 24 06:56 PM
Saccomano Nicholas APresident and CEODec 22 '25Sale2.97872587,419Dec 23 08:09 PM
Leverone Jason A.Chief Financial OfficerDec 22 '25Sale2.9730289616,301Dec 23 08:08 PM
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
PresidentDr. Nicholas A. Saccomano Ph.D.
Chief Financial OfficerMr. Jason A. Leverone CPA
Senior VP of Business Development & DirectorDr. Isaac Manke Ph.D.
M.P.H.Dr. Samuel Agresta M.D.
Chief Scientific OfficerDr. Dylan Hartley Ph.D.